AURX · Nuo Therapeutics, Inc. · Insider Trading

Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement, issued in connection with the assumption of a portion of an assigned commitment pursuant to the Amendment. The Reporting Person also holds a previously-reported separate Prepayment Restated Warrant that was issued on May 29, 2026, subject to the same vesting provision set forth in footnote (3) immediately below.

Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2027, in accordance with the Loan Agreement.

Represents Commitment, Origination Restated Second, and Capital Restate Second Warrants issued in connection with the assumption of a portion of an assigned funding commitment pursuant to the Assignment, Joinder, and Amendment No. 1 dated October 6, 2026 among the Issuer, the Reporting Person, and the other parties thereto (the "Amendment"), relating to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Loan Agreement"). The Reporting Person also holds a previously reported separate Second Restated Warrant that was issued and become exercisable on May 29, 2026.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4.

Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.

Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4.

62,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017.

15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.

The options fully vest as of June 30, 2027.

One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

The options fully vest as of June 30, 2027.

The options fully vest as of June 30, 2027.

One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.042 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

Transaction approved by Board of Directors of Issuer and Non-Employee Directors

Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement.

Transaction approved by Board of Directors of Issuer and Non-Employee Directors

Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").

Vesting (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan Agreement.

Represents Origination Interim and Capital Interim Warrants.

Transaction approved by Board of Directors of Issuer and Non-Employee Directors

Represents Origination Restated Second and Capital Restated Second Warrants.

Transaction approved by Board of Directors of Issuer and Non-Employee Directors

Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").

Transaction approved by Board of Directors of Issuer and Non-Employee Directors

Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement.

Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement.

Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.

This Form 4 amendment corrects the name of warrant issued in the form of an integrated Second Warrant, which represents Origination Second Capital Second Warrants.

Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement").

This Form 4 amendment corrects the name of warrant issued in the form of an integrated Initial Warrant, which represents Commitment Initial, Origination Initial, and Capital Initial Warrants immediately exercisable for an aggregate of 30,050 shares of Common Stock.

Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement.

Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement.

Represents a net exercise of outstanding stock options. The reporting person received 99,619 shares of common stock on the net exercise of option to purchase 125,000 shares of common stock. The issuer withheld 25,381 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.97.

Represents a net exercise of outstanding stock options. The reporting person received 55,000 shares of common stock on the net exercise of option to purchase 68,750 shares of common stock. The issuer withheld 13,750 shares of common stock underlying the option for payment of the exercise price using the closing price of $2.00.

Represents a net exercise of outstanding stock options. The reporting person received 40,909 shares of common stock on the net exercise of option to purchase 50,000 shares of common stock. The issuer withheld 9,091 shares of common stock underlying the option for payment of the exercise price using the closing price of $2.20.

The transaction reported herein was made in a private transaction to facilitate a personal real estate transaction whereby the shares of common stock acquired constitute "restricted" securities within the meaning of the Securities Act of 1933, as amended.

Represents a net exercise of outstanding stock options. The reporting person received 67,385 shares of common stock on the net exercise of option to purchase 87,500 shares of common stock. The issuer withheld 20,115 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.74.

Represents a net exercise of outstanding stock options. The reporting person received 71,397 shares of common stock on the net exercise of option to purchase 92,710 shares of common stock. The issuer withheld 21,313 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.74.

Represents a net exercise of outstanding stock options. The reporting person received 92,654 shares of common stock on the net exercise of option to purchase 120,313 shares of common stock. The issuer withheld 27,659 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.74.

Transaction approved by Board of Directors of Issuer and Non-Employee Directors